ANIX vs. ENZ, PMD, SBTX, AVIR, NBTX, URGN, ANRO, RVNC, KMDA, and FBLG
Should you be buying Anixa Biosciences stock or one of its competitors? The main competitors of Anixa Biosciences include Enzo Biochem (ENZ), Psychemedics (PMD), Silverback Therapeutics (SBTX), Atea Pharmaceuticals (AVIR), Nanobiotix (NBTX), UroGen Pharma (URGN), Alto Neuroscience (ANRO), Revance Therapeutics (RVNC), Kamada (KMDA), and FibroBiologics (FBLG). These companies are all part of the "medical" sector.
Enzo Biochem (NYSE:ENZ) and Anixa Biosciences (NASDAQ:ANIX) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, dividends, profitability, earnings, community ranking, valuation, institutional ownership, analyst recommendations and media sentiment.
Enzo Biochem has higher revenue and earnings than Anixa Biosciences.
Enzo Biochem received 193 more outperform votes than Anixa Biosciences when rated by MarketBeat users. However, 65.52% of users gave Anixa Biosciences an outperform vote while only 56.53% of users gave Enzo Biochem an outperform vote.
In the previous week, Anixa Biosciences had 12 more articles in the media than Enzo Biochem. MarketBeat recorded 12 mentions for Anixa Biosciences and 0 mentions for Enzo Biochem. Enzo Biochem's average media sentiment score of 1.35 beat Anixa Biosciences' score of 0.00 indicating that Anixa Biosciences is being referred to more favorably in the news media.
Enzo Biochem has a net margin of 99.28% compared to Enzo Biochem's net margin of 0.00%. Anixa Biosciences' return on equity of -36.71% beat Enzo Biochem's return on equity.
36.9% of Enzo Biochem shares are held by institutional investors. Comparatively, 29.1% of Anixa Biosciences shares are held by institutional investors. 15.5% of Enzo Biochem shares are held by insiders. Comparatively, 22.6% of Anixa Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Enzo Biochem has a beta of 0.78, meaning that its share price is 22% less volatile than the S&P 500. Comparatively, Anixa Biosciences has a beta of 0.84, meaning that its share price is 16% less volatile than the S&P 500.
Anixa Biosciences has a consensus price target of $7.00, suggesting a potential upside of 174.51%. Given Enzo Biochem's higher possible upside, analysts plainly believe Anixa Biosciences is more favorable than Enzo Biochem.
Summary
Anixa Biosciences beats Enzo Biochem on 8 of the 15 factors compared between the two stocks.
Get Anixa Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for ANIX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ANIX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Anixa Biosciences Competitors List
Related Companies and Tools
